Cb Innovations, LLC appears in FDA device records as the applicant for EXG PulseLinQ Cables (EXGPL), cleared through the traditional 510(k) pathway as K262816. The device sits in the cardiovascular advisory committee area, classified as a cable, transducer and electrode, patient, including connector, under regulation number 870.2900 and product code DSA. The filing was received by FDA on August 7, 2026, and decided on October 30, 2026, with a decision of substantially equivalent. The applicant address listed on the filing is 5835 Avenida Encinas, Suite 118, Carlsbad, California, and the listed applicant contact is Oxana Pantchenko. [1][3][4][9]
The documented device and its regulatory classification
EXG PulseLinQ Cables (EXGPL) is recorded as a Class II device under 21 CFR 870.2900, with the classification name Cable, Transducer And Electrode, Patient, (Including Connector), and product code DSA. FDA records place the review under the cardiovascular advisory committee and describe the clearance type as traditional, with a summary statement rather than a summary only. The third-party review flag is recorded as N. [1][3][7]
A summary document associated with the record describes the cables in relation to use with an ECG monitor or defibrillator for patient monitoring, and states that the EXG PulseLinQ Cables are substantially equivalent to the LIFEPAK ECG Cables with respect to intended use, safety, effectiveness and performance, referring readers to a device comparison table for further detail. That comparison language is the manufacturer's stated position in the filing summary, not an independent clinical finding. [7]
Submission timeline and decision
The 510(k) was received on August 7, 2026, and decided on October 30, 2026, with decision code SESE, described as substantially equivalent. The record identifies the submission as a traditional 510(k) with a summary statement, reviewed by the cardiovascular panel, and not reviewed by a third party. A separate FDA correspondence document carries different dates, dated October 11, 2026 and received October 13, 2026, alongside the same K262816 number and device name. [1][3][5]
The linked collection for this company contains one 510(k) record, and that single record carries a substantially equivalent decision. This is an as-of snapshot of the filings indexed in the collection, not a measure of total company submissions, sales, portfolio breadth or safety performance. [1][3]
Applicant identity and registration records
FDA.report lists a registration record for CB INNOVATIONS, LLC at 5835 Avenida Encinas STE 118, Carlsbad, CA 92008, with an expiration year of 2027 and the initial importer field recorded as N. The same publisher shows a GUDID contact sample tied to a device record, described as a sample rather than an exhaustive company contact directory. [6]
The filing address and the registration address match, but neither is described in the sources as a corporate headquarters, and no parent company, brand ownership or website is verified in the available records. The applicant name appears in the FDA record as Cb Innovations, LLC, while the registration listing uses the capitalized form CB INNOVATIONS, LLC. [1][4][6]
Context within product code DSA
Other 510(k) records indexed under product code DSA include the Baylis Connector Cable from Baylis Medical Technologies, Inc., decided January 18, 2026, the Multi-Link X2 ECG Cable and Leadwire System from Vyaire Medical, Inc., decided August 16, 2021, and Medtronic patient cable models decided July 12, 2021. These entries show the product code's use by other applicants and do not establish any relationship with Cb Innovations, LLC. [3]
A digital health index lists K262816 as cleared and substantially equivalent, records that the device is not on FDA's AI-enabled device list, and states that it is not tagged to any of seven digital health product types. That tagging reflects the index publisher's classification scheme, not an FDA determination about the device's technology. [9]

